Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
- SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma - - Next registration directed trial initiating with ADP-A2M4CD8 in 1H 2021 for patients with gastroesophageal cancers - - Efficacy with SPEAR T-cells in multiple solid...
- Data support confidence in SPEARHEAD-1 as a registrational trial - - Projected to complete recruitment of all patients in Q1 2021 - - Median duration of response was 28 weeks with ongoing responses beyond 72 weeks in two patients; median overall survival has not been r...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will host a virtual Investor Day on November 20, 2020 at 8AM EST/ 1PM GMT. A lin...